FR15C0082I2 - VACCINE AGAINST HPV16 AND HPV18 VIRUSES AND AT LEAST ONE OTHER TYPE OF HPV SELECTED AMONG HPV 31, 45 OR 52 - Google Patents

VACCINE AGAINST HPV16 AND HPV18 VIRUSES AND AT LEAST ONE OTHER TYPE OF HPV SELECTED AMONG HPV 31, 45 OR 52

Info

Publication number
FR15C0082I2
FR15C0082I2 FR15C0082C FR15C0082C FR15C0082I2 FR 15C0082 I2 FR15C0082 I2 FR 15C0082I2 FR 15C0082 C FR15C0082 C FR 15C0082C FR 15C0082 C FR15C0082 C FR 15C0082C FR 15C0082 I2 FR15C0082 I2 FR 15C0082I2
Authority
FR
France
Prior art keywords
hpv
type
vaccine against
against hpv16
hpv18
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR15C0082C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0413510.9A external-priority patent/GB0413510D0/en
Priority claimed from US11/114,301 external-priority patent/US20050287161A1/en
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Publication of FR15C0082I1 publication Critical patent/FR15C0082I1/en
Application granted granted Critical
Publication of FR15C0082I2 publication Critical patent/FR15C0082I2/en
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
FR15C0082C 2004-06-16 2015-12-04 VACCINE AGAINST HPV16 AND HPV18 VIRUSES AND AT LEAST ONE OTHER TYPE OF HPV SELECTED AMONG HPV 31, 45 OR 52 Active FR15C0082I2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0413510.9A GB0413510D0 (en) 2004-06-16 2004-06-16 Vaccine
US11/114,301 US20050287161A1 (en) 2002-12-20 2005-04-26 Vaccine
PCT/EP2005/006461 WO2005123125A1 (en) 2004-06-16 2005-06-14 Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31, 45 or 52

Publications (2)

Publication Number Publication Date
FR15C0082I1 FR15C0082I1 (en) 2016-01-08
FR15C0082I2 true FR15C0082I2 (en) 2016-10-28

Family

ID=35160037

Family Applications (2)

Application Number Title Priority Date Filing Date
FR15C0082C Active FR15C0082I2 (en) 2004-06-16 2015-12-04 VACCINE AGAINST HPV16 AND HPV18 VIRUSES AND AT LEAST ONE OTHER TYPE OF HPV SELECTED AMONG HPV 31, 45 OR 52
FR15C0084C Active FR15C0084I2 (en) 2004-06-16 2015-12-04 VACCINE AGAINST HPV16 AND HPV18 VIRUSES AND AT LEAST ONE OTHER TYPE OF HPV SELECTED AMONG HPV 31, 45 OR 52

Family Applications After (1)

Application Number Title Priority Date Filing Date
FR15C0084C Active FR15C0084I2 (en) 2004-06-16 2015-12-04 VACCINE AGAINST HPV16 AND HPV18 VIRUSES AND AT LEAST ONE OTHER TYPE OF HPV SELECTED AMONG HPV 31, 45 OR 52

Country Status (18)

Country Link
EP (1) EP1758609B1 (en)
JP (1) JP2008502633A (en)
KR (1) KR20070029254A (en)
AR (1) AR049354A1 (en)
AU (1) AU2005253723B2 (en)
BR (1) BRPI0512042B8 (en)
CA (1) CA2566620C (en)
FR (2) FR15C0082I2 (en)
IL (1) IL179138A0 (en)
LU (3) LU92899I2 (en)
MA (1) MA28692B1 (en)
MX (1) MXPA06014515A (en)
NO (1) NO20070195L (en)
PE (1) PE20060434A1 (en)
PL (1) PL1758609T3 (en)
RU (1) RU2420313C2 (en)
SG (1) SG153837A1 (en)
WO (1) WO2005123125A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA013325B1 (en) * 2005-04-26 2010-04-30 Глаксосмитклайн Байолоджикалс С.А. Vaccine
JP6022159B2 (en) * 2008-07-31 2016-11-09 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Anti-HPV vaccine
EP2444103B1 (en) * 2009-06-19 2017-12-20 Eyegene Inc. Vaccine for cervical cancer
NZ606949A (en) * 2010-07-15 2015-11-27 British Columbia Cancer Agency Human papillomavirus e7 antigen compositions and uses thereof
RU2015121828A (en) 2012-10-30 2016-12-20 Пфайзер Инк VACCINES BASED ON RECOMBINANT PARTICLES AGAINST HUMAN CYTOMEGALOVIRUS INFECTION
BR112017008280A2 (en) * 2014-10-24 2018-01-02 Hpvvax, Llc. method for treating a patient
CN107188966B (en) 2016-03-15 2020-03-31 中国医学科学院基础医学研究所 Papilloma virus chimeric protein and application thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
GB9921147D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
US6908613B2 (en) * 2000-06-21 2005-06-21 Medimmune, Inc. Chimeric human papillomavirus (HPV) L1 molecules and uses therefor
GB0110431D0 (en) * 2001-04-27 2001-06-20 Glaxosmithkline Biolog Sa Novel compounds
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206359D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
WO2004056389A1 (en) * 2002-12-20 2004-07-08 Glaxosmithkline Biologicals Sa Hpv-16 and -18 l1 vlp vaccine

Also Published As

Publication number Publication date
CA2566620A1 (en) 2005-12-29
FR15C0084I1 (en) 2016-01-08
RU2420313C2 (en) 2011-06-10
FR15C0084I2 (en) 2016-10-28
FR15C0082I1 (en) 2016-01-08
AU2005253723B2 (en) 2011-01-20
LU92898I2 (en) 2016-03-08
CA2566620C (en) 2014-03-11
JP2008502633A (en) 2008-01-31
AU2005253723A1 (en) 2005-12-29
SG153837A1 (en) 2009-07-29
NO20070195L (en) 2007-01-15
BRPI0512042B1 (en) 2019-01-22
PL1758609T3 (en) 2013-02-28
AR049354A1 (en) 2006-07-19
BRPI0512042A (en) 2008-02-06
EP1758609B1 (en) 2012-10-03
IL179138A0 (en) 2007-03-08
KR20070029254A (en) 2007-03-13
WO2005123125A1 (en) 2005-12-29
MXPA06014515A (en) 2007-03-23
PE20060434A1 (en) 2006-06-08
MA28692B1 (en) 2007-06-01
LU92900I2 (en) 2016-03-08
LU92899I2 (en) 2016-03-08
BRPI0512042B8 (en) 2021-05-25
EP1758609A1 (en) 2007-03-07
RU2006143804A (en) 2008-08-20

Similar Documents

Publication Publication Date Title
FR15C0082I2 (en) VACCINE AGAINST HPV16 AND HPV18 VIRUSES AND AT LEAST ONE OTHER TYPE OF HPV SELECTED AMONG HPV 31, 45 OR 52
NO2017005I1 (en) Human papillomavirus vaccine [types 6, 11, 16, 18, 31, 33, 45, 52, 58]
ECSP045300A (en) VIRAL ANTIGENS
AP2313A (en) Inhibitors of hepatitis C virus RNA-dependent RNA ploymerase, and compositions and treatments using the same.
BRPI0309631A2 (en) tetravalent dengue vaccine containing a trivial deletion of 30 nucleotides in the utr-31 'of dengue types 1,2,3, and 4, or chimeric dengue antigenic viruses 1,2,3 and 4
IL189329A (en) Vaccination against dengue virus infection, kit and use of same
WO2009039248A8 (en) Methods of treating a flaviviridae family viral infection and compositions for treating a flaviviridae family viral infection
HK1085378A1 (en) Use of hpv16 and hpv18 as vaccine against one or more of oncogenic hpv type 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68
WO2010047830A3 (en) Agents for hcv treatment
AU2003246373A1 (en) Recombinant measles viruses expressing epitopes pf antigens of rna viruses and use of the recombinant viruses for the preparation of vaccine compositions
HUS1500059I1 (en) Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31, 45 or 52
NO20053348D0 (en) Pharmaceutical composition for the treatment of viral attacks.
MY149395A (en) Pharmaceutical compound capable of induce immune protective response against dengue virus having the capsid protein of the dengue virus
EP1765330A4 (en) Pyranoindole derivatives and the use thereof for the treatment of hepatitis c virus infection or disease
AU2005279590A1 (en) Vaccine composition against hepatitis C virus
WO2005023849A3 (en) Antigenic peptides of rabies virus and uses thereof
WO2007076091A3 (en) Treatment of viral infections using a tissue factor inhibitor
FR15C0080I2 (en) VACCINE AGAINST HPV16 AND HPV18 VIRUSES AND AT LEAST ONE OTHER TYPE OF HPV SELECTED AMONG HPV 31, 45 OR 52
WO2006019841A3 (en) Treatment of viral infections with egr 1 activators
SI1572233T1 (en) Use of HPV16 and HPV18 as vaccine against one or more of oncogenic HPV type 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68
EP1901071A4 (en) Methods of diagnosing, preventing and treating infection with hepatitis c virus
WO2006114273A3 (en) Vaccine
AU2003240866A1 (en) Antibodies, peptides and vaccines against hiv-1 virus
WO2008070332A3 (en) Feline influenza vaccine and method of use
FI20050246A0 (en) Diagnosis of viruses